Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
ADMA Biologics

ADMA Biologics (NASDAQ: ADMA) insider transactions

In the twelve months to 10 November 2026, executives and directors of ADMA Biologics reported 11 open-market sales of 241,096 shares ($3.3m) and 5 open-market purchases of 45,400 shares ($468,294), by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in ADMA Biologics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
5 November 2026Grossman Adam SPresident and CEOOption exercise, 10b5-1 plan+105,000$5.402,217,777Form 4
5 November 2026Grossman Adam SPresident and CEOOpen-market sale, 10b5-1 plan−105,000$12.002,112,777Form 4
5 November 2026Grossman Adam SPresident and CEOOpen-market sale, 10b5-1 plan−42,000$12.002,070,777Form 4
24 July 2026Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceShares withheld for tax−3,177$8.37443,061Form 4
16 July 2026Kohler TerryCFO and TreasurerGrant or award+85,130—143,149Form 4
27 May 2026Grossman Jerrold BDirectorOpen-market purchase+6,400$7.91520,284Form 4
12 May 2026Grossman Jerrold BDirectorOpen-market purchase+12,500$8.01513,884Form 4
11 May 2026Grossman Jerrold BDirectorOpen-market purchase+12,500$8.01501,384Form 4
1 April 2026Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceShares withheld for tax−20,362$9.11446,238Form 4
17 March 2026Guiheen Lawrence P.DirectorGift−30,000—105,520Form 4
17 March 2026Guiheen Lawrence P.DirectorGift+30,000—30,000Form 4
16 March 2026Grossman Adam SPresident and CEOOption exercise+15,000$5.402,133,777Form 4
16 March 2026Grossman Adam SPresident and CEOOpen-market sale−15,000$15.162,118,777Form 4
16 March 2026Grossman Adam SPresident and CEOOpen-market sale−6,000$15.162,112,777Form 4
13 March 2026Guiheen Lawrence P.DirectorOption exercise+30,000$3.66135,520Form 4
9 March 2026Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOther−91,266—466,600Form 4
9 March 2026Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise+2,500$5.00469,100Form 4
9 March 2026Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise+1,250$4.31470,350Form 4
9 March 2026Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise+2,646$2.83472,996Form 4
9 March 2026Kestenberg-Messina Kaitlin M.COO and SVP, ComplianceOption exercise+1,525$2.35474,521Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ADMA Biologics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.